This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mohr, J. F.
Right arrow Articles by Ostrosky-Zeichner, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mohr, J. F.
Right arrow Articles by Ostrosky-Zeichner, L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2004, p. 3151-3153, Vol. 48, No. 8
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.8.3151-3153.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics of Intravenous Itraconazole in Stable Hemodialysis Patients

John F. Mohr,1* Kevin W. Finkel,2 John H. Rex,1,{dagger} Jose R. Rodriguez,1 Gerhard J. Leitz,3 and Luis Ostrosky-Zeichner1

Division of Infectious Diseases and Center for the Study of Emerging and Re-emerging Pathogens,1 Department of Nephrology, University of Texas Health Science Center, Houston, Texas,2 Ortho-Biotech Products L.P., Bridgewater, New Jersey3

Received 1 December 2003/ Returned for modification 7 March 2004/ Accepted 28 April 2004

The pharmacokinetics of intravenous itraconazole (ITC) was studied in dialysis patients. Dialysis had no effect on the half-life and clearance of ITC or OH-ITC. However, dialysis allowed the clearance of hydroxypropyl-ß-cyclodextrin (HP-ß-CD). The area under the concentration-time curve from time zero to infinity (AUC0-{infty}) for HP-ß-CD administered before dialysis was lower than the AUC0-{infty} when it was administered after dialysis (P < 0.01). Administration of ITC intravenously just prior to hemodialysis appears to produce adequate systemic exposures of ITC and OH-ITC while allowing dialysis clearance of HP-ß-CD. Studies of multiple administrations are warranted.

* Corresponding author. Mailing address: University of Texas Health Science Center Houston, Department of Infectious Diseases, 6431 Fannin, JFB 1.728, Houston, TX 77030. Phone: (713) 500-6742. Fax: (713) 500-5495. E-mail: john.mohr{at}uth.tmc.edu.

{dagger} Present address: AstraZeneca, Macclesfield, Cheshire, United Kingdom SK10 4TF.

Antimicrobial Agents and Chemotherapy, August 2004, p. 3151-3153, Vol. 48, No. 8
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.8.3151-3153.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Fuhrmann, V., Schenk, P., Jaeger, W., Miksits, M., Kneidinger, N., Warszawska, J., Holzinger, U., Kitzberger, R., Thalhammer, F. (2007). Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. J Antimicrob Chemother 60: 1085-1090 [Abstract] [Full Text]  
  • Mouton, J. W., van Peer, A., de Beule, K., Van Vliet, A., Donnelly, J. P., Soons, P. A. (2006). Pharmacokinetics of Itraconazole and Hydroxyitraconazole in Healthy Subjects after Single and Multiple Doses of a Novel Formulation. Antimicrob. Agents Chemother. 50: 4096-4102 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2005). In Vitro Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species to Itraconazole: Global Survey of 9,359 Isolates Tested by Clinical and Laboratory Standards Institute Broth Microdilution Methods. J. Clin. Microbiol. 43: 3807-3810 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»